Jaguar Health Raises $1.5M in Private Placement
Ticker: JAGX · Form: 8-K · Filed: 2024-07-16T00:00:00.000Z
Sentiment: neutral
Topics: private-placement, equity-securities, capital-raise
TL;DR
Jaguar Health just closed a $1.5M private placement, raising cash but selling stock without registration.
AI Summary
Jaguar Health, Inc. announced on July 15, 2024, the closing of a private placement of its common stock, raising approximately $1.5 million. The company also issued warrants to purchase additional shares. This offering was conducted without registration under the Securities Act of 1933.
Why It Matters
This capital infusion provides Jaguar Health with additional funds, which could be used for ongoing operations or future development, while the unregistered sale indicates a need for immediate funding.
Risk Assessment
Risk Level: medium — The unregistered sale of equity securities suggests the company may be facing financial pressures or seeking capital quickly, which can carry inherent risks for investors.
Key Numbers
- $1.5M — Gross Proceeds (Raised from the private placement of common stock.)
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- $1.5 million (dollar_amount) — Gross proceeds from private placement
- July 15, 2024 (date) — Date of closing for private placement
- Securities Act of 1933 (legal_document) — Regulation under which securities were sold
FAQ
What was the total amount of gross proceeds raised in the private placement?
The company raised approximately $1.5 million in gross proceeds from the private placement.
On what date did Jaguar Health, Inc. close this private placement?
The private placement was closed on July 15, 2024.
Were the securities sold in this private placement registered under the Securities Act of 1933?
No, the securities were sold in a private placement conducted without registration under the Securities Act of 1933.
What type of securities were sold in the private placement?
The private placement involved the sale of common stock and warrants to purchase common stock.
What is the principal executive office address for Jaguar Health, Inc.?
The principal executive offices are located at 200 Pine Street, Suite 400, San Francisco, California 94104.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-07-16 17:18:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar
- $1,851,850 — stock to such holder in exchange for a $1,851,850 reduction in the outstanding balance of
Filing Documents
- tm2419563d1_8k.htm (8-K) — 26KB
- 0001104659-24-080244.txt ( ) — 196KB
- jagx-20240715.xsd (EX-101.SCH) — 3KB
- jagx-20240715_lab.xml (EX-101.LAB) — 33KB
- jagx-20240715_pre.xml (EX-101.PRE) — 22KB
- tm2419563d1_8k_htm.xml (XML) — 4KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. On July 15, 2024, Jaguar Health, Inc. (the "Company") entered into a privately negotiated exchange agreement (the "Exchange Agreement") with a holder of royalty interest in the Company. Pursuant to the Exchange Agreement, the Company issued 455,000 shares of common stock to such holder in exchange for a $1,851,850 reduction in the outstanding balance of the royalty interest held by such holder. The shares of common stock that were issued in the exchange transaction described above were issued in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933, as amended. The form of Exchange Agreement was filed as Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019, filed on August 14, 2019, which is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Form of Exchange Agreement (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019, filed on August 14, 2019). 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: July 16, 2024